UCB Secures FDA Approval for KYGEVVI, the First-Ever Treatment for Ultra-Rare TK2 Deficiency
UCB, a global biopharmaceutical company, has received U.S. Food and Drug Administration (FDA) approval for KYGEVVI, a treatment for adults and pediatric patients suffering from…
Read More...
Read More...
